G1 Therapeutics Inc. (NASDAQ: GTHX) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
G1 Therapeutics Inc. (NASDAQ: GTHX) is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA(TM) (trilaciclib), the first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer. G1 has a deep clinical pipeline…